Health ❯ Healthcare ❯ Drug Development

Clinical Trials

FDA Approval Regulatory Approval Real-World Evidence Alzheimer's Disease Phase 2 Trials Eli Lilly Side Effects Innovative Therapies GBT-601 Pharmaceutical Innovations Neuropharmacology Neurodegenerative Diseases Randomized Controlled Trials Market Dynamics AI in Medicine CAPLYTA Late-Stage Studies Weight-loss Medications Repurposed Medications Gene Therapy Innovations Antibiotic Resistance CNS Disorders Weight Loss Treatments Combination Therapies mRNA Vaccines Alzheimer's Treatments Oncology Camizestrant Immunology Treatments NHS Innovations Preclinical Research Market Trends Neuropsychiatric Drugs Bronchodilators Chronic Lung Conditions Wegovy Monoclonal Antibodies Safety Monitoring Pain Relief Medications Cancer Pain Relief Orforglipron Efficacy Studies Gilead Sciences Phase III Studies Phase 3 Clinical Studies Lecanemab Phase 1 Trials Weight Loss Medications Targeted Therapy Future Research Directions Metabolic Disease Therapies Nuzolvence Cancer Medications Obesity Drug Candidates Next-Gen Therapies Weight Loss Therapies Selective Estrogen Receptor Degraders Regulatory Submissions Therapeutic Applications Focal Segmental Glomerulosclerosis PALOMA-3 Trial Oncology Assets Vaccine Trials Investigational Drugs Azer-cel Therapeutic Products Amyloid Immunotherapy Semaglutide Epinephrine Alternatives Tumor-Infiltrating Lymphocytes Alzheimer's Disease Treatments Regulatory Exclusivity Biosimilar Approval Process Leqembi

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

An FDA decision on a subcutaneous starting dose for Leqembi is due by May 24.

TG Therapeutics Lifts 2026 Outlook After Strong Briumvi Year, Shares Jump

BioMarin to Acquire Amicus for $4.8 Billion in Cash

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Study Finds CBD–THC Combination Kills Ovarian Cancer Cells in Lab

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Tops Q3 Forecasts, Raises Profit Outlook

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Arecor and Sequel to Co-Develop AT278 With Twiist AID for High-Dose Diabetes Care

Cambridge Researchers Demonstrate Tumor-Triggered Two-Part STING Prodrug

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks

Johns Hopkins Researchers Grow Vascularized Whole-Brain Organoid With Network-Level Activity

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline